Keros Therapeutics (KROS) Net Margin (2019 - 2025)
Keros Therapeutics filings provide 6 years of Net Margin readings, the most recent being 4066.03% for Q4 2025.
- On a quarterly basis, Net Margin fell 1312627.0% to 4066.03% in Q4 2025 year-over-year; TTM through Dec 2025 was 35.62%, a 15609188.0% decrease, with the full-year FY2025 number at 35.65%, changed N/A from a year prior.
- Net Margin hit 4066.03% in Q4 2025 for Keros Therapeutics, down from 51.04% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 9060.24% in Q4 2024 to a low of 493000.0% in Q3 2023.
- Median Net Margin over the past 5 years was 168.96% (2025), compared with a mean of 49612.82%.
- Biggest five-year swings in Net Margin: surged 47935155bps in 2024 and later tumbled -1312627bps in 2025.
- Keros Therapeutics' Net Margin stood at 38.77% in 2021, then tumbled by -247bps to 134.37% in 2022, then crashed by -20844bps to 28141.96% in 2023, then soared by 132bps to 9060.24% in 2024, then plummeted by -145bps to 4066.03% in 2025.
- The last three reported values for Net Margin were 4066.03% (Q4 2025), 51.04% (Q3 2025), and 168.96% (Q2 2025) per Business Quant data.